<DOC>
	<DOCNO>NCT00279422</DOCNO>
	<brief_summary>The purpose study compare efficacy visilizumab placebo subject intravenous steroid-refractory ulcerative colitis .</brief_summary>
	<brief_title>A Study Visilizumab Subjects With Intravenous Steroid-Refractory Ulcerative Colitis</brief_title>
	<detailed_description>PDL BioPharma , Inc. formerly know Protein Design Labs , Inc .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Males female , 18 year age old . Diagnosis ulcerative colitis ( UC ) verify endoscopy within 60 month prior consent . Severe active disease , define Modified Truelove &amp; Witts Severity Index ( MTWSI ; also know Lichtiger score ) ≥ 11 consent , confirmatory MTWSI ≥ 10 fifth consecutive day intravenous ( IV ) steroid within 1 day prior randomization . Mayo score ≥ 10 Mayo mucosal subscore ≥ 2 minimum 3 consecutive day ( ie , fourth consecutive day ) IV steroid . Adequate contraception day consent 3 month last dose study drug . Negative serum pregnancy test . Negative Clostridium difficile test . Signed date informed consent Health Insurance Portability Accountability Act ( HIPAA ) applicable . UC require immediate intervention toxic megacolon require imminent intervention . History total proctocolectomy , subtotal colectomy ileorectal anastomosis . Presence Ileostomy . White blood cell count le 2.5 x 10^3/mcL ; platelet count le 150 x 10^3/mcL ; hemoglobin level less 8 g/dL . Active medically significant infection , particularly viral etiology , eg , know cytomegalovirus ( CMV ) colitis . This include incidence medically significant opportunistic infection within past 12 month . Live vaccination within 6 week prior randomization . Significant organ dysfunction , include cardiac , renal , liver , central nervous system ( CNS ) , pulmonary , vascular , gastrointestinal , endocrine , laboratory abnormality . History myocardial infarction , coronary artery disease , congestive heart failure , arrythmias within 6 month prior consent . History treatment lymphoproliferative disorder ( LPD ) malignancy within past 5 year ( exclude nonmelanoma skin cancer carcinoma situ cervix ) . Seropositivity infection human immunodeficiency virus ( HIV1 ) , hepatitis B virus ( HBV ) surface antigen , hepatitis C virus ( HCV ) . Pregnancy nursing . Treatment first dose infliximab another antitumor necrosis factor ( TNF ) α drug within 4 week randomization , treatment subsequent dose antiTNFα drug within 2 week randomization . Treatment cyclosporine tacrolimus ( FK506 ) within 2 week prior randomization . Treatment investigational drug therapy within 60 day prior randomization , except mention two exclusion criterion . Unable willing discontinue UC drug ( include , limited 6mercaptopurine , azathioprine , methotrexate ) , except glucocorticoid 5ASA , immediately prior randomization . Nontherapeutic level chronic antiseizure medication subject prior history seizure . Any condition , investigator 's opinion , make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Intravenous , Steroid-Refractory , Ulcerative Colitis</keyword>
</DOC>